Sinclair IS partners with Quintiles to commercialize portfolio in Mexico

UK-based Sinclair IS Pharma (AIM: SPH.L) yesterday announced the signing of a 10-year collaboration and licensing agreement for biopharma services company Quintiles (Rowfarma Mexico) to commercialize the firm’s portfolio of dermo-cosmetic products and medical devices in Mexico.

Under the agreement, Quintiles will handle the entire process including regulatory submissions; product importation, warehousing and distribution to wholesalers; sales force promotion to dermatologists and plastic surgeons; and marketing, advertising and promotion.

“This collaboration, a further step in Latin America, supports our company’s growth strategy, to move our product portfolio into fast-growing, emerging markets through strategic, regional partnerships,” said Chris Spooner, chief executive of Sinclair IS, noting that “Quintiles’ extensive commercialization experience and proven track record in Mexico and other emerging markets made it the clear choice to help us execute our strategy.”